About This Deal

BIO-RAD LABORATORIES, INC. acquired Celsee, Inc. for $99.3 million total consideration, including fair value of contingent consideration of up to $60.0 million payable on certain 2021-2022 net-revenue achievement, a transaction completed in April 2020, structured as all cash plus contingent consideration.

Celsee, Inc. operates in Life Science. Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells.

We believe this acquisition will complement our Life Science product offerings.

Single-cell isolation and analysis platform adjacent to Bio-Rad's Life Science franchise. Complements Life Science product offerings. Life Science segment

Deal Terms

Acquirer
BIO-RAD LABORATORIES, INC.
Target
Celsee, Inc.
Value
$99.3 million total consideration, including fair value of contingent consideration of up to $60.0 million payable on certain 2021-2022 net-revenue achievement
Date
April 2020
Type
Full acquisition
Status
Ready

Transaction Details

Segment
Life Science
Structure
all cash plus contingent consideration
Announced
April 1, 2020
Closed
April 1, 2020
Synergies
Complements Life Science product offerings.

In Their Words

Celsee is a manufacturer of instruments and consumables for the isolation, detection, and analysis of single cells. We believe this acquisition will complement our Life Science product offerings.Bio-Rad Laboratories FY2020 10-K, Acquisitions note

Advisors

Advisory firms were not disclosed for this transaction.

Related Deals & Entities

Sources: Press release ↗ · Last updated June 11, 2026

See how VectorShift works for your firm

Request Demo